Skip to main content
NEURIZON THERAPEUTICS LIMITED logo

NEURIZON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · NUZ ISIN · AU0000357261 LEI · 529900O3S715CU3F0342 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,410 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country AU Australia
Listing ASX NUZ

About NEURIZON THERAPEUTICS LIMITED

https://www.neurizon.com/

Neurizon Therapeutics Limited is a clinical-stage company dedicated to the development of novel treatments for neurodegenerative diseases. The company's lead therapeutic candidate is monepantel (MPL), a small molecule compound that functions as a potent mTOR pathway modulator. By stimulating autophagy, monepantel aims to facilitate the clearance of misfolded protein aggregates associated with neuronal decay. The primary clinical focus is Amyotrophic Lateral Sclerosis (ALS) and Motor Neurone Disease (MND), where the candidate is being evaluated in advanced clinical trials. Neurizon's approach targets the fundamental biological drivers of neurodegeneration to slow disease progression and improve patient outcomes. The development program is supported by clinical data demonstrating the drug's safety, tolerability, and potential to impact biomarkers of neurodegeneration.

Recent filings

Filing Released Lang Actions
HEALEY ALS Trial Regimen I Expands to 240 Participants 3 pages 417.4KB
Regulatory Filings Classification · 82% confidence The document is a corporate press release announcing the expansion of a clinical trial cohort (Regimen I of the HEALEY ALS Platform Trial). It does not present financial statements, proxy materials, management discussions, or regulatory filings under a specific form. It is an operational update rather than a report of quarter/full-year results, a director change, a dividend notice, or an investor presentation. Therefore it falls under the fallback category for miscellaneous regulatory/corporate announcements: Regulatory Filings (RNS).
2026-05-26 English
Ethics Approval Received for NUZ-001 Oral Liquid P1 Study 2 pages 293.4KB
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing ethics approval for a Phase 1 study of a drug formulation. It contains no financial statements, regulatory form references, meeting materials, or investor presentation content; instead it reports operational progress. Such miscellaneous corporate announcements are classified under Regulatory Filings (RNS).
2026-05-12 English
Initial Director's Interest Notice 2 pages 363.4KB
Director's Dealing Classification · 85% confidence The document is an ASX Appendix 3X Initial Director’s Interest Notice under Listing Rule 3.19A.1. It reports a director’s personal share interests (or lack thereof) upon appointment. This is a classic insider transaction notice, classifying it as a Director’s Dealing filing.
2026-05-11 English
Final Director's Interest Notice 2 pages 345.3KB
Director's Dealing Classification · 93% confidence The document is an ASX Appendix 3Z “Final Director’s Interest Notice” under listing rule 3.19A.3, detailing the director’s holdings of performance rights, options, and shares. It reports insider share interests and changes in a director’s stakes. This corresponds to a Director’s Dealing filing.
2026-05-11 English
Australian Microcap Investment Conference Presentation 27 pages 19.8MB
Investor Presentation Classification · 92% confidence The document is an investor conference slide deck titled “Australian Microcap Investment Conference presentation” by Neurizon, including detailed slide content, clinical data charts, trial design, disclaimers, and company strategy. It is not merely a short notice announcing that a report is available (RPA) but contains the full presentation itself. Therefore, this is an Investor Presentation (IP).
2026-05-10 English
Neurizon Strengthens Board for the Next Growth Phase 3 pages 309.8KB
Board/Management Information Classification · 100% confidence The document is an announcement about the appointment of a new Independent Non-Executive Director and the retirement of an existing board member. It focuses on changes in the company's board composition and governance. There is no financial data, no report attached or referenced as being published, and no mention of regulatory filings or certifications. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2026-05-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.